Supreme court allows licensees to challenge patents - artechnica (10 Jan 07)
The Supreme Court has decided that respiratory drug maker MedImmune can dispute the validity of a patent it licenses from Genentech. The Supreme Court’s decision reverses a Federal Circuit Appeals court ruling and establishes a new legal precedent with broad implications and the potential to disrupt many long-standing licensing agreements. Companies are now considered to have the requisite legal standing to challenge patents even if they pay to license them. This shift in patent policy could make it more difficult for large companies to use dubious and questionable patents to perpetually extort licensing fees from smaller companies…This decision reflects a trend towards serious patent reform and
willingness to throw out older precedents in order to make the patent
system more fair and reasonable.